Welcome to epgonline.org - the website for healthcare professionals

What's new?

  • ,AIKN CDI May Update

    Anti-Infectives Knowledge Network (AIKN) CDI Updates

    The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI) has
    recently been updated with new content including presentation slides from EBMT and
    ECCMID 2015, a gut microflora animation unveiled at the Astellas stand during
    ECCMID 2015, recent articles added to the ‘CDI perspectives’ section and the
    opportunity to participate in a second round consensus questionnaire for the
    ​largest ever clinician consensus report.

    May 2015 MYC/15/0020/EUb

  • ,Whats New CSU

    Launch of Chronic Spontaneous Urticaria (CSU)
    Knowledge Centre

    A new Chronic Spontaneous Urticaria (CSU) Knowledge Centre has
    launched on epgonline.org to raise awareness and improve early diagnosis
    of the condition. Healthcare professionals will have free access to a
    disease overview, recent symposia highlights, a video channel and useful resources.

  • ,Whats new Psoriasis Knowledge centre

    Launch of Psoriasis Knowledge Centre

    A new Psoriasis Knowledge Centre has launched on epgonline.org
    to provide dermatologists, family medicine physicians and other healthcare
    professionals with free access to relevant information on psoriasis including
    pathophysiology, comorbidities, signs and symptoms, diagnosis and more.

  • ,What's New ECCMID IFI

    Anti-Infectives Knowledge Network (AIKN) IFI Updates

    The AIKN-IFI has been updated with four presentations from the Astellas-sponsored
    symposium at the 25th European Congress of Clinical Microbiology and Infectious
    Diseases (ECCMID) 2015
    . The congress took place on 25–28 April in Copenhagen,
    Denmark. Visit the congresses section of this resource to view and download the slides
    free of charge.

    May 2015 MYC/15/0040/EUb

  • ,

    New Therapy Focus area for
    type 2 diabetes launched

    This free resource has recently launched on epgonline.org containing information
    for healthcare professionals based in Europe on the use of incretin‐insulin treatment
    combinations for type 2 diabetes. Explore five informative sections focused on the role
    emerging incretin‐based therapies can play in the long‐term treatment and management of
    type 2 diabetes.

Latest News

Baxalta commences business


Baxalta, spun out of Baxter, launches on 1 July 2015 to develop and promote products in haematology, immunology and to expand its oncology business. Prime products for haematology include Advate, Bebulin, Feiba, Hemofilm, Obizumab, Recombinate and ...

Topline safety results from Phase III trial of LPCN 1021 in hypogonadal men- Lipocine


Lipocine announced top-line 52-week safety results from its SOAR pivotal Phase III clinical study evaluating efficacy and safety of LPCN 1021, an oral testosterone product candidate, in hypogonadal men with low testosterone. Overall, LPCN 1021 was ...

PRISM II study of Nuedexta (dextromethorphan and quinidine sulphate) reports data for treating pseudobulbar affect- Avanir Pharma


Avanir Pharmaceuticals announced top-line data from the PRISM II study showing that treatment with Nuedexta (dextromethorphan and quinidine sulphate) was associated with a statistically significant reduction in symptoms of pseudobulbar affect (PBA) ...

CHMP recommends approval of Respreeza (alpha1-antitrypsin), for alpha-1 antitrypsin deficiency- CSL Behring


The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Respreeza (alpha1-antitrypsin), from CSL Behring, indicated to treat patients with alpha-1 antitrypsin deficiency ...

Phase III trials of ocrelizumab report positive results in multiple sclerosis- Genentech


Genentech has announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most ...

EU gives Vent-Os Sinus Dilation System CE mark approval for sinusitis- SinuSys Corp


SinuSys Corp has announced receipt of the CE Mark for Vent-Os Sinus Dilation System, a low-pressure, self-expanding dilation device to treat frontal and sphenoid sinusitis, in addition to maxillary disease. In a prospective, multi-center clinical ...

INT 747 (obeticholic acid) filed with FDA and EMA for primary biliary cirrhosis- Intercept Pharmaceuticals


Intercept Pharmaceuticals announced two regulatory milestones for INT 747 (obeticholic acid or OCA) in primary biliary cirrhosis (PBC): submission of a New Drug Application for accelerated approval to the FDA and acceptance of the Marketing ...

Recent Updates


Clinical Guidelines

Anaemia management in people with chronic kidney disease

Lower urinary tract symptoms: The management of lower urinary tract symptoms in men

Suspected cancer: recognition and referral (NG12)

Bronchiolitis in children

Medical Journals

Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial.

Consequences of AphanizomenonFlos-aquae(AFA) extract (Stemtech (TM) ) on metabolic profile of patients with type 2 diabetes.

The evaluation of inflammatory and oxidative stress biomarkers on coffee-diabetes association: results from the 10-year follow-up of the ATTICA Study (2002-2012).

Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes.

epgonline.org Social

Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors